公开(公告)号：US11530251B2

公开(公告)日：2022-12-20

申请号：US16417048

申请日：2019-05-20

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD

Inventor： Abraham Rutenberg ,  Ronny Uzana ,  Michal Lotem ,  Arthur Machlenkin ,  Galit Eisenberg ,  Tamar Peretz-Yablonsky ,  Shoshana Frankenburg ,  Roni Engelstein

IPC: C07K14/705 ,  A61K38/17 ,  A61K35/17 ,  A61P35/00 ,  C12N5/0783 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

公开(公告)号：US10344073B2

公开(公告)日：2019-07-09

申请号：US15110111

申请日：2015-01-08

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Abraham Rutenberg ,  Ronny Uzana ,  Michal Lotem ,  Arthur Machlenkin ,  Galit Eisenberg ,  Tamar Peretz-Yablonsky ,  Shoshana Frankenburg ,  Roni Engelstein

IPC: C07K14/705 ,  C07K14/725 ,  A61K39/39 ,  A61K39/395 ,  A61K35/17 ,  C12N5/0783 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.